Related Experiment Videos
High activity of mitoxantrone in previously untreated low-grade lymphomas
S W Hansen1, N I Nissen, M M Hansen
1Department of Medicine, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.
Abstract:
A consecutive series of 21 previously untreated patients with low-grade non-Hodgkin lymphomas were treated with mitoxantrone 5 mg/m2 daily for 3 days every 3 weeks. The cumulative dose did not exceed 165 mg/m2 in any patient. In this group, 7 patients had small lymphocytic lymphomas, 10 patients had follicular small cleaved cell lymphomas, and 4 patients had follicular mixed small- and large-cell lymphomas. Of the 21 patients, 20 obtained remission (complete in 6, partial in 14), and 15 of these are still in remission. Relapse-free survival is 68% at 2 years. None of the patients has died. Nonhematologic toxicity was modest. No severe alopecia was seen, and only 6 patients had nausea and vomiting (WHO grade 1-3). No cardiac toxicity was seen. In conclusion, mitoxantrone is a highly active and well-tolerated drug in this subset of patients. Hematologic toxicity, especially leukopenia, was dose limiting, and a reduction of the dose was necessary in 15 out of the 21 patients.
Insights
Mitoxantrone effectively treats low-grade non-Hodgkin lymphomas, achieving high remission rates in previously untreated patients. While generally well-tolerated, hematologic toxicity, particularly leukopenia, was dose-limiting.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Low-grade non-Hodgkin lymphomas (NHL) represent a heterogeneous group of lymphoid malignancies.
- Effective and well-tolerated treatment options for these indolent lymphomas are crucial for patient outcomes.
- Mitoxantrone, an anthracenedione antineoplastic agent, has shown activity in various cancers.
Purpose of the Study:
- To evaluate the efficacy and toxicity of mitoxantrone in patients with previously untreated low-grade non-Hodgkin lymphomas.
- To determine remission rates, duration of remission, and survival outcomes.
- To assess the safety profile, including nonhematologic and hematologic toxicity.
Main Methods:
- A consecutive series of 21 untreated patients with low-grade NHL received mitoxantrone (5 mg/m2 daily for 3 days every 3 weeks).
- The cumulative dose was capped at 165 mg/m2.
- Patient subgroups included small lymphocytic lymphomas, follicular small cleaved cell lymphomas, and follicular mixed small- and large-cell lymphomas.
Main Results:
- A high overall remission rate of 95% (20 out of 21 patients) was observed, with 6 complete and 14 partial remissions.
- 15 patients remain in remission, and the 2-year relapse-free survival is 68%.
- Nonhematologic toxicity was mild (e.g., nausea, vomiting), with no severe alopecia or cardiac toxicity. Hematologic toxicity, primarily leukopenia, was dose-limiting in 15 patients, necessitating dose reduction.
Conclusions:
- Mitoxantrone demonstrates high activity and a favorable safety profile in previously untreated patients with low-grade non-Hodgkin lymphomas.
- The drug is well-tolerated regarding nonhematologic side effects, but hematologic toxicity requires careful monitoring and dose adjustment.
- Mitoxantrone represents a promising therapeutic option for this patient population, warranting further investigation.